Advertisement

Drug Racemization and Its Significance in Pharmaceutical Research

  • M. Reist
  • B. Testa
  • P.-A. Carrupt
Part of the Handbook of Experimental Pharmacology book series (HEP, volume 153)

Abstract

The presence of one or more elements of chirality (i.e., centers, axes or planes of chirality, and generally helicity) (Cahn et al. 1966; Testa 1979) in drug molecules generates specific properties which may be advantageous in some cases, but inevitably require special consideration and studies. Examples of advantages include the possibility of increased selectivity and the fact that chirality per se is an invaluable probe in molecular pharmacology and biochemistry (Testa 1989,1990; Testa and Trager 1990). In contrast, problems generated by stereoisomerism include the need for stereospecific synthetic and analytical methods, the influence of the degree of resolution on activity (Barlow et al. 1972), and the increased complexity of metabolic, pharmacological, and clinical studies (AriËns 1986; Testa et al. 1993a).

Keywords

Pharmaceutical Research Configurational Stability Chiral Compound Chiral HPLC Chiral Drug 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Allenmark S (1991) Chromatographic Enantioseparation: Methods and Applications. Ellis Horwood, LondonGoogle Scholar
  2. Ariens EJ (1986) Stereochemistry: a source of problems in medicinal chemistry. Med Res Rev 6:451–466PubMedCrossRefGoogle Scholar
  3. Aso Y, Yoshioka S, Shibazaki T, Uchiyama M (1988) The kinetics of the racemization of oxazepam in aqueous solution. Chem Pharm Bull 36:1834–1840PubMedCrossRefGoogle Scholar
  4. Barlow RB, Franks FM, Pearson JDM (1972) The relation between biological activity and the degree of optical resolution of optical isomers. J Pharm Pharmacol 24: 753–761PubMedCrossRefGoogle Scholar
  5. Beckmann R (1963) Ueber das Verhalten von Thalidomid im Organismus. Arzneim-Forsch 13:185–191Google Scholar
  6. Cahn RS, Ingold C, Prelog V (1966) Specification of molecular chirality. Angew Chem Int Ed 5:385–415CrossRefGoogle Scholar
  7. Chen TL, Vogelsang GB, Petty BG, Brundrett RB, Noe DA, Santos GW, Colvin OM (1989) Plasma pharmacokinetics and urinary excretion of thalidomide after oral dosing in healthy male volunteers. Drug Metab Dispos 17:402–405PubMedGoogle Scholar
  8. Coward JK, Bruice TC (1969) Intramolecular amine-catalyzed ketone enolization. A search for concerted intramolecular general-base, general-acid catalysis. J Am Chem Soc 91:5339–5345CrossRefGoogle Scholar
  9. Cram DJ, Cram JM (1973) Carbanions and carbonium ions—stereochemical analogs. Intra Science Chem Rep 7:1–17Google Scholar
  10. Cram DJ, Kingsbury CA, Rickborn B (1961) Electrophilic substitution at saturated carbon. XIV. Asymmetric solvation of carbanions in stereospecific hydrogendeuterium exchange reactions. J Am Chem Soc 83:3688–3696CrossRefGoogle Scholar
  11. Eriksson T, Björkman S, Roth B, Fyge A, Höglund P (1995) Stereospecific determination, chiral inversion in vitro and pharmacokinetics in humans of the enantiomers of thalidomide. Chirality 7:44–52PubMedCrossRefGoogle Scholar
  12. Gu L, Strickley RG (1987) Diketopiperazine formation, hydrolysis, and epimerization of the new dipeptide angiotensin-converting enzyme inhibitor RS-10085. Pharm Res 4:392–397PubMedCrossRefGoogle Scholar
  13. Hoffmann K, Schneider-Scherzer E, Kleinkauf H, Zocher R (1994) Purification and characterization of eucaryotic alanine racemase acting as key enzyme in cyclosporin biosynthesis. J Biol Chem 269:12710–12714PubMedGoogle Scholar
  14. Holmberg B (1913) Stereochemie der halogensubstituierten Bernsteinsäuren. J Prakt Chem 88:553–603CrossRefGoogle Scholar
  15. Hsü SK, Wilson CL (1936) Optical activity in relation to tautomeric change. Part VI. Comparison of the rates of racemization and of bromination of a ketone. A Further study under conditions of basic catalysis. J Chem Soc 623–625Google Scholar
  16. Hsü SK, Ingold CK, Wilson CL (1938) Prototropy in relation to the exchange of hydrogen isotopes. Part III. Comparison of the rates of racemization and of hydrogen exchange in α-acidic ketone. J Chem Soc 78–81Google Scholar
  17. Ingold CK, Wilson CL (1934) Optical activity in relation to tautomeric change. Part IV. Comparison of the rates of racemization and of bromination of a ketone. J Chem Soc 773–777Google Scholar
  18. Kawazoe Y, Ohnishi M (1964) Quantitative analysis of active hydrogen by nuclear magnetic resonance. Chem Pharm Bull 11:846–848Google Scholar
  19. Knoche B, Blaschke G (1994) Investigations on the in vitro racemization of thalidomide by high-performance liquid chromatography. J Chromatogr 666:235–240CrossRefGoogle Scholar
  20. Koch H (1981) Die Arenoxid-Hypothese der Thalidomid-Wirkung. Ueberlegungen zum molekularen Wirkungsmechanismus des “klassischen” Teratogens. Sci Pharm 49:67–99Google Scholar
  21. Lickefett H, Krohn K, König WA, Gehrcke B, Syldatk C (1993) Enantioseparation of 5-monosubstituted hydantoins by capillary gas chromatography—investigation of chemical and enzymatic racemization. Tetrahedron Asym 4:1129–1135CrossRefGoogle Scholar
  22. March J (1985) Advanced Organic Chemistry. Wiley, New York, pp 512–575Google Scholar
  23. Matsuo H, Kawazoe Y, Sato M, Ohnishi M, Tatsuno T (1967) Studies on the racemization of amino acids and their derivatives. I. On the deuterium-hydrogen exchange reaction of amino acid derivatives in basic media. Chem Pharm Bull 15:391–398CrossRefGoogle Scholar
  24. Mayer JM (1990) Stereoselective metabolism of antiinflammatory 2-arylpropionates. Acta Pharm Nord 2:197–216PubMedGoogle Scholar
  25. Mayer JM, Young M, Testa B, Etter JC (1989) Modelling the metabolic epimerization of antiinflammatory 2-arylpropanoyl-coenzyme-A conjugates: solvent effects on the 1H/2H exchange in S-[2-(dimethylamino)ethyl] 2-phenylpropanethioate. Helv Chim Acta 72:1225–1232CrossRefGoogle Scholar
  26. Mellin GW, Katzenstein M (1962) The saga of thalidomide: neuropathy to embryopathy, with case reports and congenital anomalies. N Eng J Med 267:1184–1244CrossRefGoogle Scholar
  27. Mitra B, Kallarakal AT, Kozarich JW, Gerlt JA, Clifton JG, Petsko GA, Kenyon GL (1995) Mechanism of the reaction catalyzed by mandelate racemase: importance of electrophilic catalysis by glutamic acid 317. Biochemistry 34:2777–2787PubMedCrossRefGoogle Scholar
  28. Moreira AL, Corral LG, Ye W, Johnson B, Stirling D, Muller GW, Freedman VH, Kaplan G (1997) Thalidomide and thalidomide analogs reduce HIV type 1 replication in human macrophages in vitro. AIDS Res Hum Retrov 13:857–863CrossRefGoogle Scholar
  29. Nunes MA, Brochmann-Hanssen E (1974) Hydrolysis and epimerization kinetics of pilocarpine in aqueous solution. J Pharm Sci 63:716–721PubMedCrossRefGoogle Scholar
  30. Ockenfels H, Köhler F, Meise W (1976) Teratogenic effect and stereospecificity of a thalidomide metabolite. Pharmazie 31:492–493PubMedGoogle Scholar
  31. Peters Jr T (1996) All about Albumin. Biochemistry, Genetics, and Medical Applications. Academic Press, San Diego, pp 9–75Google Scholar
  32. Rama Sastry BV (1981) Anticholinergics: antispasmodic and antiulcer drugs. In: Wolff ME (ed) Burger’s Medicinal Chemistry, Fourth Edition, Part III. Wiley, New York, p 371Google Scholar
  33. Reist M, Testa B, Carrupt PA, Jung M, Schurig V (1995a) Racemization, enantiomerization, diastereomerization, and epimerization: their meaning and pharmacological significance. Chirality 7:396–400CrossRefGoogle Scholar
  34. Reist M, Christiansen LH, Christoffersen P, Carrupt PA, Testa B (1995b) Low configurational stability of amfepramone and cathinone: mechanism and kinetics of chiral inversion. Chirality 7:469–473CrossRefGoogle Scholar
  35. Reist M, Carrupt PA, Testa B, Lehmann S, Hansen JJ (1996) Kinetics and mechanisms of racemization: 5-substituted hydantoins (= imidazoline-2,4-diones) as models of chiral drugs. Helv Chim Acta 79:767–778CrossRefGoogle Scholar
  36. Reist M, Testa B, Carrupt PA (1997) The racemization of enantiopure drugs: helping medicinal chemists to approach the problem. Enantiomer 2:147–155Google Scholar
  37. Reist M, Carrupt PA, Francotte E, Testa B (1998) Chiral inversion and hydrolysis of thalidomide: mechanisms and catalysis by bases and serum albumin, and chiral stability of teratogenic metabolites. Chem Res Toxicol 11:1521–1528PubMedCrossRefGoogle Scholar
  38. Reist M, Roy-de Vos M, Montseny JP, Mayer JM, Carrupt PA, Berger Y, Testa B (2000) Very slow chiral inversion of Clopidogrel in rats: a pharmacokinetic and mechanistic investigation. Drug Metal Disposit 28:1405–1410Google Scholar
  39. Roitman JN, Cram DJ (1971) Electrophilic substitution at saturated carbon. XLV. Dissection of mechanisms of base catalyzed hydrogen-deuterium exchange of carbon acids into inversion, isoinversion, and racemization pathways. J Am Chem Soc 93:2225–2243CrossRefGoogle Scholar
  40. Sanders JKM, Hunter BK (1993) Modern NMR Spectroscopy: a Guide for Chemists. Oxford University Press, Oxford, pp 33–52Google Scholar
  41. Schmitz W, Albers C, Fingerhut R, Conzelmann E (1995) Purification and characterization of an alpha-methylacyl-CoA racemase from human liver. Eur J Biochem 231:815–822PubMedCrossRefGoogle Scholar
  42. Schumacher H, Smith RL, Williams RT (1965a) The metabolism of thalidomide: the fate of thalidomide and some of its hydrolysis products in various species. Br J Pharmacol 25:338–351Google Scholar
  43. Schumacher H, Smith RL, Williams RT (1965b) The metabolism of thalidomide: the spontaneous hydrolysis of thalidomide in solution. Br J Pharmacol 25:324–337Google Scholar
  44. Shannon EJ, Morales EJ, Sandoval F (1997) Immunomodulatory assays to study structure-activity relationships of thalidomide. Immunopharmacology 35:203–212PubMedCrossRefGoogle Scholar
  45. Sheskin J (1965) Thalidomide in the treatment of lepra reactions. Clin Pharmacol Ther 6:303–306PubMedGoogle Scholar
  46. Stevens RJ, Andujar C, Edwards CJ, Ames PR, Barwick AR, Khamashta MA, Hughes GR (1997) Thalidomide in the treatment of the cutaneous manifestations of lupus erythematosus: experience in sixteen consecutive patients. Br J Rheumatol 36:353–359PubMedCrossRefGoogle Scholar
  47. Testa B (1973) Some chemical and stereochemical aspects of diethylpropion metabolism in man. Acta Pharm Suec 10:441–454PubMedGoogle Scholar
  48. Testa B (1979) Principles of Organic Stereochemistry. Dekker, New YorkGoogle Scholar
  49. Testa B (1989) Mechanisms of chiral recognition in xenobiotic metabolism and drugreceptor interactions. Chirality 1:7–9PubMedCrossRefGoogle Scholar
  50. Testa B (1990) Definitions and concepts in biochirality. In: Holmstedt B, Frank H, Testa B (eds) Chirality and Biological Activity. Liss, New York, pp 15–32Google Scholar
  51. Testa B (1995) The Metabolism of Drugs and other Xenobiotics—Biochemistry of Redox Reactions. Academic Press, LondonGoogle Scholar
  52. Testa B, Jenner P (1976) Drug Metabolism: Chemical and Biochemical Aspects. Dekker, New YorkGoogle Scholar
  53. Testa B, Jenner P (1978) Stereochemical methodology. In: Garrett ER, Hirtz JL (eds) Drug Fate and Metabolism: Methods and Techniques. Dekker, New York, pp 143–193Google Scholar
  54. Testa B, Trager WF (1990) Racemates versus enantiomers in drug development: dogmatism or pragmatism? Chirality 2:129–133PubMedCrossRefGoogle Scholar
  55. Testa B, Carrupt PA, Christiansen LH, Christoffersen P, Reist M (1993a) Chirality in drug research: stereomania, stereophobia, or stereophilia? In: Ciaassen V (ed) Trends in Receptor Research. Elsevier, Amsterdam, pp 1–8Google Scholar
  56. Testa B, Carrupt PA, Gal J (1993b) The so-called “interconversion” of stereoisomeric drugs: an attempt at clarification. Chirality 5:105–111PubMedCrossRefGoogle Scholar
  57. Tokuyama S, Hatano K (1995) Purification and properties of thermostable N- acylamino acid racemase from Amycolatopsis sp. TS-1-60. Applied Microbiol Biotechnol 42:853–859CrossRefGoogle Scholar
  58. Vogelsang GB, Farmer ER, Hess AD, Altamonte V, Beschorner WE, Jabs DA, Corio RL, Levin LS, Colvin OM, Wingard JR (1992) Thalidomide for the treatment of chronic graft-versus-host disease. N Eng J Med 326:1055–1058CrossRefGoogle Scholar
  59. Werner A (1911) Ueber den räumlichen Stellungswechsel bei Umsetzungen von raumisomeren Verbindungen. Berichte 44:873–882Google Scholar
  60. Yagasaki M, Iwata K, Ishino S, Azuma M, Ozaki A (1995) Cloning, purification, and properties of a cofactor-independent glutamate racemase from Lactobacillus brevis ATCC 8287. Biosci Biotechnol Biochem 59:610–614PubMedCrossRefGoogle Scholar
  61. Yamauchi T, Choi SY, Okada H, Yohda M, Kumagai H, Esaki N, Soda K (1992) Properties of aspartate racemase, a pyridoxal 5’-phosphate-independent amino acid racemase. J Biol Chem 267:18361–18364PubMedGoogle Scholar
  62. Zini R, Barré J, Brée F, Tillement JP, Sébille B (1981) Evidence for a concentration-dependent polymerization of a commercial human serum albumin. J Chromatogr 216:191–198PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2003

Authors and Affiliations

  • M. Reist
  • B. Testa
  • P.-A. Carrupt

There are no affiliations available

Personalised recommendations